<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554255</url>
  </required_header>
  <id_info>
    <org_study_id>108543</org_study_id>
    <nct_id>NCT00554255</nct_id>
  </id_info>
  <brief_title>A Study of SB751689 in Japanese Postmenopausal Women</brief_title>
  <official_title>Phase I Study of SB751689 - Single and Multiple Oral Dose Study in Japanese Postmenopausal Women -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and tolerability, PK and PD of SB751689 following single and 5-day&#xD;
      multiple oral doses of 100, 200, and 400 mg in Japanese postmenopausal subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 23, 2006</start_date>
  <completion_date type="Actual">December 12, 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, change in clinical laboratory tests, vital signs, 12lead ECG</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Pharmacodynamics of SB751689</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB751689</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is considered as healthy by the investigator at screening.&#xD;
&#xD;
          -  Healthy subjects are defined as individuals who are free from clinically significant&#xD;
             illness or disease as determined by their medical history, physical examination,&#xD;
             laboratory studies, and other tests&#xD;
&#xD;
          -  Japanese healthy postmenopausal woman as defined as being amenorrheic for at least 1&#xD;
             year at screening with &lt;157.79mIU/mL of FSH levels.&#xD;
&#xD;
          -  Body weight &gt;= 45 kg and BMI within the range 18.5 -25.0 kg/m2.&#xD;
&#xD;
          -  The subject is within the following criteria as screening;Liver function tests (ALT,&#xD;
             AST, GGT, alkaline phosphatase, total bilirubin), CPK, serum parathyroid hormone&#xD;
             (iPTH) test, vitamin D (1,25(OH2 D3)) levels, Serum calcium&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Non-smokers (at least 6 months)&#xD;
&#xD;
          -  The subject is able to attend all visits and complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any clinically relevant abnormality on medical examination, vital&#xD;
             sign, clinical laboratory test or medical history at screening in the medical opinion&#xD;
             of the investigator or the subject has a medical history that is not considered as&#xD;
             eligible for inclusion in this study by the investigator.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications or components thereof (except&#xD;
             pollenosis without any signs or symptoms).&#xD;
&#xD;
          -  Participation in a clinical study or post-marketing study with an investigational or a&#xD;
             non-investigational product or device within 4 months of preceding the first dose of&#xD;
             study medication.&#xD;
&#xD;
          -  Participation in another clinical study or post-marketing study in which the subject&#xD;
             is or will be exposed to an investigational or a non-investigational product or&#xD;
             device.&#xD;
&#xD;
          -  Positive for syphilis, HIV antibody, hepatitis B antigen or hepatitis C antibody,&#xD;
             HTLV-1 antibody at screening.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Donation of blood in excess of 400 mL within the previous 4 months or 200mL within the&#xD;
             previous 1 month of screening.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, herbal and dietary supplements, within&#xD;
             14 days prior to the first dose of study medication.&#xD;
&#xD;
          -  History of drug abuse or current conditions of drug abuse or alcoholism.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 7 units/week (&gt;350mL of beer/unit)&#xD;
             within 6 months of screening.&#xD;
&#xD;
          -  Subjects with a history of renal, hepatic, or biliary disease.&#xD;
&#xD;
          -  History of clinically significant cardiovascular disease.&#xD;
&#xD;
          -  History of pernicious anemia, pancreatitis, osteosarcoma or kidney stones.&#xD;
&#xD;
          -  Subjects who have had history of significant gastrointestinal disease (e.g.,&#xD;
             gastrointestinal malabsorptive disease, colostomy, chronic gastroesophageal reflux&#xD;
             disease, Crohn's disease, ulcerative colitis, gastric or duodenal ulcer,&#xD;
             gastrointestinal tract bleeding, short bowel syndrome, sprue, lactose intolerance,&#xD;
             irritable bowel syndrome).&#xD;
&#xD;
          -  Subjects with any history of a gastrointestinal surgical procedure that might affect&#xD;
             the absorption of SB-751689 (e.g. cholecystectomy, gastrointestinal bypass surgery,&#xD;
             partial or total gastrectomy, small bowel resection).&#xD;
&#xD;
          -  Medical conditions which might alter bone metabolism, including hyperparathyroidism,&#xD;
             hypoparathyroidism, hyperthyroidism, hypothyroidism, Paget's disease, malabsorption,&#xD;
             or Cushing's syndrome, and hypogonadism, hypocalcemia, hypercalcemia,&#xD;
             hypophosphatemia, hypomagnesemia, hypermagnesemia, osteopetrosis, osteomalacia, and&#xD;
             recent (within one year) history of fracture or prolonged bedrest.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
    </facility>
  </location>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Japanese</keyword>
  <keyword>safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

